Round Rock Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Round Rock Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-265	Closed	-$205K	–	339
2026 Q1	$205K	Sell	265 -200	-43%	-$153K	0.03%	310
2025 Q4	$359K	Buy	465 +5	+1%	+$3.4K	0.05%	247
2025 Q3	$259K	Sell	460 -300	-39%	-$170K	0.04%	272
2025 Q2	$399K	Buy	760 +396	+109%	+$221K	0.07%	152
2025 Q1	$231K	Buy	364 +4	+1%	+$2.75K	0.04%	192
2024 Q4	$256K	Hold	360	–	–	0.05%	179
2024 Q3	$378K	Hold	360	–	–	0.09%	130
2024 Q2	$378K	Sell	360 -8	-2%	-$7.75K	0.09%	126
2024 Q1	$354K	Sell	368 -92	-20%	-$87.5K	0.08%	145
2023 Q4	$404K	Hold	460	–	–	0.1%	126
2023 Q3	$379K	Hold	460	–	–	0.14%	96
2023 Q2	$331K	Buy	460 +100	+28%	+$77.1K	0.12%	109
2023 Q1	$296K	Hold	360	–	–	0.11%	119
2022 Q4	$260K	Sell	360 -10	-3%	-$7.38K	0.11%	128
2022 Q3	$255K	Hold	370	–	–	0.12%	121
2022 Q2	$219K	Buy	+370	New	+$241K	0.1%	129

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Round Rock Advisors's REGN Position: Q2 2026 in Review

Round Rock Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 265 shares — an estimated $205K sold.

Round Rock Advisors first reported a position in REGN in Q2 2022 and held it in 16 quarters. The position peaked at $404K in Q4 2023. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Round Rock Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Round Rock Advisors sold 265 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $205K.
Round Rock Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2022 and held it in 16 quarters.
Round Rock Advisors's Regeneron Pharmaceuticals position peaked at $404K in Q4 2023.
1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Round Rock Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.